2024 Afm24 clinical

Afm24 clinical

Author: irpr

August undefined, 2024

WebThe functional response of natural killer (NK) cells is tightly regulated by transcription factors (TFs). The TFs enable NK cells to adapt to… WebFeb 6, 2024 · AFM24 is a tetravalent bispecific (anti-human EGFR x anti-human CD16A) innate immune cell engaging recombinant antibody construct being developed to target …

AFM24 in combination with atezolizumab in patients with …

WebJul 30, 2024 · To advance AFM24 into clinical development, the safety of . AFM24 in cynomolgus monkeys was determined in a 28-day . toxicity study with repeated intravenous infusion (2-hour infu- WebFeb 3, 2024 · AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24 is a tetravalent bispecific (anti … bandrupturen

Affimed Announces Collaboration with Roche to Study AFM24 in ...

WebFeb 26, 2024 · AFM24 is a form of immunotherapy that acts as a bridge between innate immune cells — the first line of defense against threats — and cancer cells. Called an innate cell engager (ICE), the treatment works by binding to proteins on both cell types, bringing immune cells closer to the tumor site for more effective killing. WebNov 5, 2024 · AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in … Web• Safety and tolerability of AFM24 in combination with SNK01 cells • Preliminary efficacy; assessed by evaluating progression-free survival (PFS) and overall survival (OS) (as per RECIST v1.1) Phase 2a • Safety and tolerability of AFM24 in combination with SNK01 cells • PFS, OS, duration of response clinical benefit rate artur baron

Study to Assess AFM24 in Advanced Solid Cancers

Full article: Preclinical evaluation of AFM24, a novel CD16A …

WebMay 26, 2024 · AFM24 utilizes the patient’s innate immunity to redirect and activate immune cells, overcoming resistance to current therapies. The primary mode of action of AFM24 … WebAFM24, an EGFR-directed ICE®(innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing.8The differentiated MOA does not rely on the EGFR signaling pathway for tumor killing but instead uses EGFR … art urbanismeWebJun 2, 2024 · AFM24 is a first in class, tetravalent, bispecific, novel ICE targeting EGFR. By binding to EGFR on tumor cells and CD16A on innate immune cells, AFM24 may utilize … bandruptur hand icd

"WebPrism Research provides efficient, high quality Phase I-IV clinical trial capabilities and services for special population and complex Phase I trials, assisting pharmaceutical and … " - Afm24 clinical

Afm24 clinical

The combination of CD16A/EGFR innate cell engager, AFM24, …

WebApr 27, 2024 · Affimed and NKGen Biotech have initiated a phase 1/2a study (AFM24-103), investigating AFM24 in combination with SNK01, NKGen Biotech’s NK cell product (NCT05099549). About Affimed N.V. WebFeb 3, 2024 · As Minnesota’s Cancer Center, we have served the entire state for more than 25 years. Our researchers, educators, and care providers have worked to discover the …

Did you know?

WebBased Practice Clinical Scholar Program 800 East 28th Street Minneapolis, MN 55407 612-863-4000 allinahealth.org/abbottnorthwestern 338663 0318 ©2024 ALLINA HEALTH … WebSep 4, 2024 · Affimed is evaluating AFM24 as a monotherapy (AFM24-101) for patients with advanced EGFR-expressing solid malignancies whose disease has progressed after …

Webmetastatic colorectal cancerand non-small cell lung cancer. AFM24 is a tetravalent bispecific (anti-human EGFRx anti-human CD16A) innate immune cell engaging recombinant antibody construct being developed to target EGFR-expressing solid tumors . and has been designed to specifically utilize the cytotoxic potential of the innate WebApr 8, 2024 · AFM24 is a tetravalent, bispecific innate cell engager (ICE®) that activates the innate immune system by binding to CD16A on innate immune cells and EGFR, a protein widely expressed on solid tumors, to kill cancer cells.

WebJun 2, 2024 · Background: AFM24 is a first-in-class, tetravalent, bispecific, fragment crystallizable-silenced antibody that targets epidermal growth factor receptor-expressing (EGFR+) solid tumors. Of its 4 binding sites, 2 are specific for EGFR, and 2 are specific for CD16A, the Fcγ receptor expressed by natural killer (NK) cells and macrophages. WebApr 10, 2024 · Clinical success story (based on AFM13, AFM24): Superior safety profile compared to other treatment options; Utility across multiple indications; Well suited for combinations: Synergy with NK cells; Synergy with CPIs; 5 Attachments. Original Link Original Document Permalink ...

WebSep 4, 2024 · AFM24 is a tetravalent, bispecific innate cell engager (ICE ®) that activates the innate immune system by binding to CD16A on innate immune cells and EGFR, a protein widely expressed on solid tumors, to kill cancer cells.

WebJun 29, 2024 · Affimed continues to enroll patients in all three AFM24 clinical trials and is planning to present data in the second half of this year. This should reveal the efficacy of the company's three ... artur belovWebJan 7, 2024 · AFM24-101, a Phase 1/ 2 a clinical trial of AFM24, the EGFR/CD16A targeted ICE ® for treatment of patients with EGFR-expressing solid tumors,... Heidelberg, Germany, January 7, 2024– Affimed N ... artur bauder tu dortmundWebAFM24 & SNK01 THERAPY • AFM24 is a tetravalent bispecific innate cell engager (ICE®) derived from the redirected optimized cell killing (ROCK®) antibody platform • AFM24 … arturban statueWebA Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers Erkrankung artur begyanWebAffimed has cleared the investigational new drug (IND) stage and is now initiating a clinical trial of AFM24 in patients with tumors known to express EGFR, putting it on a path that could lead to ... artur bergmanWebSep 4, 2024 · Affimed is evaluating AFM24 as a monotherapy (AFM24-101) for patients with advanced EGFR-expressing solid malignancies whose disease has progressed after … bandruptur lftaWebA third of patients evaluated (8 out of 24) responded to the immunotherapy and saw their cancer stop growing after being treated with AFM24. This is a promising finding for a phase I clinical trial, as early-phase trials are typically run in patients who have very advanced cancers as a last resort. artur bbb